United States

ViroMed Co Ltd (084990.KQ)

084990.KQ on KOSDAQ - Korea Secs Dealers Association Quotation

25 May 2017
Change (% chg)

₩-1,300.00 (-1.35%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

VM Biopharma obtained INDA from Korean healh regulator for mid-stage trial of gene therapy drug
Tuesday, 2 Aug 2016 09:00am EDT 

Viromed Co Ltd <084990.KQ> :Obtained inda from ministry of food and drug safety in korea for phase ii clinical trial of investigational gene therapy drug, vm202.  Full Article

ViroMed to raise 182.66 bln won via rights issue
Thursday, 21 Jul 2016 04:32am EDT 

ViroMed <084990.KQ> Co Ltd: Rights issue of 1.65 million common shares of par value 500 won each . Issue price of 110,700 won per share, for proceeds of 182.66 billion won . Shareholders of record on Sept. 6 will have rights to purchase 0.1153341264 rights share for each share held during Oct. 17 to Oct. 18 .Listing date of Nov. 7 for the new shares.  Full Article

ViroMed announces patent granted
Thursday, 7 Jul 2016 02:03am EDT 

ViroMed Co.,Ltd. <084990.KQ>:Says it receives a patent on July 6, for adenovirus producing novel cell line and the use thereof.  Full Article

ViroMed announces patent granted
Tuesday, 21 Jun 2016 01:15am EDT 

ViroMedCo.,Ltd. <084990.KQ>:Says it receives a patent on June 14, for gene therapy for diabetic neuropathy using an HGF isoform.  Full Article

ViroMed completes private placement of common shares
Tuesday, 22 Mar 2016 01:41am EDT 

ViroMed Co Ltd:Completes private placement of 108,383 shares of common stock and raised proceeds of 15,000,207,200 won from the issuance.  Full Article

ViroMed announces private placement of common shares
Friday, 18 Mar 2016 01:23am EDT 

ViroMed Co Ltd:To issue 108,383 shares of common stock through private placement, with par value of 500 won per share, for debt-equity swap.Sets issue price at 138,400 won per share, to raise proceeds of 15,000,207,200 won for operations.Listing date of April 5 for the new shares.  Full Article

bluebird bio and ViroMed Enter into License Agreement for Antibodies to Develop Chimeric Antigen Receptor T Cell Therapy
Thursday, 3 Dec 2015 08:00am EST 

bluebird bio, Inc. and ViroMed Co., Ltd:Says they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using ViroMed's humanized antibody to an undisclosed cancer target for solid tumors.Under the terms of the agreement, ViroMed will provide bluebird bio exclusive rights to its novel humanized antibody to the target, and bluebird bio will leverage its lentiviral gene therapy platform and CAR T capabilities to develop CAR T therapies against the target.Financial terms of the agreement include a $1 million upfront payment and subsequent milestone payments to ViroMed, which together could total over $48 million per licensed product if certain development and regulatory milestones are achieved.ViroMed is also eligible to receive tiered royalties on product sales. bluebird bio will conduct and fund clinical development as well as regulatory and commercial activities.  Full Article

More From Around the Web